Greenwich LifeSciences, Inc. (GLSI): Shareholders' Equity
$353.2K
As of 2025-12-31
$3.12M
As of 2026-06-30
-70.1%
3-year compound annual growth
-58.2%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $353.2K | -61.1% | 2026-06-01, Balance as of period end |
| 2024-12-31 | $908.6K | -86.4% | 2026-06-01, Balance as of period end |
| 2023-12-31 | $6.70M | -49.3% | 2025-04-15, Balance as of period end |
| 2022-12-31 | $13.21M | -50.8% | 2024-04-15, Balance as of period end |
| 2021-12-31 | $26.83M | -2.9% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $27.63M | n/m | 2022-03-21, Balance as of period end |
| 2019-12-31 | -$1.35M | n/a | 2021-03-31, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | 2025-12-31 | $353.2K | -61.1% |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | $3.83M | -24.2% |
| Vyome Holdings, Inc (HIND) | 2025-12-31 | $3.76M | n/m |
| Kairos Pharma, Ltd. (KAPA) | 2025-12-31 | $6.34M | +32.8% |
| Ernexa Therapeutics Inc. (ERNA) | 2025-12-31 | $2.40M | +41.2% |
| Adial Pharmaceuticals, Inc. (ADIL) | 2025-12-31 | $5.28M | +29.7% |
| CDT Equity Inc. (CDT) | 2025-12-31 | -$7.17M | n/m |
| OS Therapies Inc (OSTX) | 2025-12-31 | -$6.10M | n/m |
| Jupiter Neurosciences, Inc. (JUNS) | 2025-12-31 | -$1.83M | n/m |
Compare GLSI, GOVX, HIND, KAPA side by side · Screen every company in Pharmaceutical Preparations ↗